Purchase this article with an account.
G. Miura, M. Kitahashi, M. Kubota, Y. Mitamura, S. Yamamoto; Two Year Results of Photodynamic Therapy for Polypoidal Choroidal Vasculopathy. Invest. Ophthalmol. Vis. Sci. 2009;50(13):242.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the 2 year outcome of photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV).
This retrospective study involved 56 eyes of 55 PCV patients followed for at least 24 months after PDT. The best-corrected visual acuity (BCVA), fluorescein and indocyanine green angiographic results, and foveal thicknesses were investigated before and after PDT.
The mean number of PDT treatments was 1.6±0.7. Twenty-four eyes (42.9%) required retreatment by PDT because of recurrences. The mean period until the first recurrence was 11.4±7.4 months. The mean BCVA was 0.73±0.20 logMAR units before the initial PDT, 0.65±0.45 logMAR units at 12 months, and 0.75±0.53 logMAR units at 24 months. The mean fovea thickness was 459.4±210.2 µm before the initial PDT, 235.3±177.6 µm at 12 months, and 238.5±189.6 µm at 24 months postoperatively. The BCVA in 41 eyes (73%) did not change (within ±0.2 logMAR units) or improve (>0.2 logMAR units) before and 24 months after PDT. However, the BCVA in 11 eyes (45%) of the 24 eyes that had had a recurrence worsened to >0.2 logMAR units during the 24 months follow-up period.
PDT is an effective treatment to preserve VA against PCV. However, approximately 43% of all cases had a recurrence within 24 months, and 11% had the first recurrence 18 months after their first PDT treatment. Once PCV recurred, the VA prognosis worsened significantly. Long-term careful observation is needed for PCV after PDT treatment.
This PDF is available to Subscribers Only